U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination
    • Showing Current items.

    RFC3 replication factor C subunit 3 [ Homo sapiens (human) ]

    Gene ID: 5983, updated on 27-Nov-2024

    GeneRIFs: Gene References Into Functions

    GeneRIFPubMed TitleDate
    Abnormal activation of RFC3, A YAP1/TEAD downstream target, promotes gastric cancer progression.

    Abnormal activation of RFC3, A YAP1/TEAD downstream target, promotes gastric cancer progression.
    Guo Z, Guo L.

    03/28/2024
    RFC3 serves as a novel prognostic biomarker and target for head and neck squamous cell carcinoma.

    RFC3 serves as a novel prognostic biomarker and target for head and neck squamous cell carcinoma.
    Avs KR, Pandi C, Kannan B, Pandi A, Jayaseelan VP, Arumugam P.

    11/13/2023
    IRF2 inhibits ZIKV replication by promoting FAM111A expression to enhance the host restriction effect of RFC3.

    IRF2 inhibits ZIKV replication by promoting FAM111A expression to enhance the host restriction effect of RFC3.
    Ren K, Zhu Y, Sun H, Li S, Duan X, Li S, Li Y, Li B, Chen L., Free PMC Article

    03/19/2022
    Ectopic expression of RFC3 induced epithelialmesenchymal transition (EMT), as determined by downregulation of Ecadherin, and upregulation of Ncadherin, vimentin and Wnt signaling target genes, including cMYC, Wnt1 and betacatenin, and the ratio of phosphorylatedglycogen synthase kinase 3 (GSK3)beta (Ser9)/GSK3beta.

    RFC3 induces epithelial‑mesenchymal transition in lung adenocarcinoma cells through the Wnt/β‑catenin pathway and possesses prognostic value in lung adenocarcinoma.
    Gong S, Qu X, Yang S, Zhou S, Li P, Zhang Q., Free PMC Article

    04/18/2020
    The expression level of RFC3 was markedly upregulated in the HCC tissues and cells.

    shRNA-mediated silencing of the RFC3 gene suppresses hepatocellular carcinoma cell proliferation.
    Yao Z, Hu K, Huang H, Xu S, Wang Q, Zhang P, Yang P, Liu B.

    09/10/2016
    The expression level of RFC3 was remarkably up-regulated in ovarian cancer OVCAR-3 cells. Down-regulation of RFC3 expression arrested the cell cycle of OVCAR-3 cell in the S-phase and induced apoptosis.

    ShRNA-mediated silencing of the RFC3 gene suppress ovarian tumor cells proliferation.
    Shen H, Xu J, Zhao S, Shi H, Yao S, Jiang N., Free PMC Article

    08/6/2016
    High RFC3 expression is associated with neoplastic myelopoiesis.

    Replication factor C3 is a CREB target gene that regulates cell cycle progression through the modulation of chromatin loading of PCNA.
    Chae HD, Mitton B, Lacayo NJ, Sakamoto KM., Free PMC Article

    08/29/2015
    our findings suggest that RFC3 protein is an important and independent biomarker with prognostic implications for patients with ovarian carcinoma.

    Overexpression of RFC3 is correlated with ovarian tumor development and poor prognosis.
    Shen H, Cai M, Zhao S, Wang H, Li M, Yao S, Jiang N.

    01/10/2015
    9-cis-RA-activated RXRalpha suppresses the growth of retinoid-sensitive breast cancer and embryonic cells through RFC3.

    9-Cis-retinoic acid induces growth inhibition in retinoid-sensitive breast cancer and sea urchin embryonic cells via retinoid X receptor α and replication factor C3.
    Maeng S, Kim GJ, Choi EJ, Yang HO, Lee DS, Sohn YC., Free PMC Article

    04/20/2013
    Data identified RFC3 as a candidate oncogene amplified in esophageal adenocarcinoma (EAC).

    Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma.
    Lockwood WW, Thu KL, Lin L, Pikor LA, Chari R, Lam WL, Beer DG., Free PMC Article

    08/25/2012
    RFC3 mutation and loss of RFC3 expression occur in large fractions of gastric and colorectal cancers and suggest that these alterations may contribute to the cancer pathogenesis by deregulating DNA repair and replication.

    Mutational and expressional analysis of RFC3, a clamp loader in DNA replication, in gastric and colorectal cancers.
    Kim YR, Song SY, Kim SS, An CH, Lee SH, Yoo NJ.

    10/23/2010
    Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)

    Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
    Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, Keavney B, Yusuf S, Gerstein HC, Engert JC, Anand S, DREAM investigators., Free PMC Article

    09/15/2010
    Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator)

    Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.
    Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR., Free PMC Article

    06/30/2010
    Observational study of gene-disease association. (HuGE Navigator)See all PubMed (3) articles

    Polymorphisms in the base excision repair pathway and graft-versus-host disease.
    Arora M, Lindgren B, Basu S, Nagaraj S, Gross M, Weisdorf D, Thyagarajan B.

    Association between genetic variants in the base excision repair pathway and outcomes after hematopoietic cell transplantations.
    Thyagarajan B, Lindgren B, Basu S, Nagaraj S, Gross MD, Weisdorf DJ, Arora M.

    Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.
    Talmud PJ, Drenos F, Shah S, Shah T, Palmen J, Verzilli C, Gaunt TR, Pallas J, Lovering R, Li K, Casas JP, Sofat R, Kumari M, Rodriguez S, Johnson T, Newhouse SJ, Dominiczak A, Samani NJ, Caulfield M, Sever P, Stanton A, Shields DC, Padmanabhan S, Melander O, Hastie C, Delles C, Ebrahim S, Marmot MG, Smith GD, Lawlor DA, Munroe PB, Day IN, Kivimaki M, Whittaker J, Humphries SE, Hingorani AD, ASCOT investigators, NORDIL investigators, BRIGHT Consortium.

    06/30/2010
    Observational study of gene-disease association, gene-gene interaction, and gene-environment interaction. (HuGE Navigator)

    Genetic polymorphisms in 85 DNA repair genes and bladder cancer risk.
    Michiels S, Laplanche A, Boulet T, Dessen P, Guillonneau B, Méjean A, Desgrandchamps F, Lathrop M, Sarasin A, Benhamou S.

    03/25/2009
    firstprevious page of 1 nextlast